A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Clinical trial NCT05006716 · RECRUITING

Trial details

NCT number: NCT05006716
Sponsor: BeOne Medicines
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Malignancy Marginal Zone Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma Waldenström Macroglobulinemia Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma

Start date: 2021-09-13
Primary completion: 2026-11-01
Enrollment: 645

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.